Pfizer Drops Phase II Glaucoma Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug maker remains committed to joint research program with NicOx, however, and will proceed with follow-up compounds.
You may also be interested in...
NicOx Buys Back Glaucoma Drug Rights From Pfizer
The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.
NicOx Buys Back Glaucoma Drug Rights From Pfizer
The French biotech looks to deal the drug even as it continues to focus on the development of its other main asset, the still unpartnered naproxcinod for osteoarthritis.
NicOx Envisions Co-Commercialization And In-Licensing Strategy Around Naproxcinod
French firm plans to build U.S. sales force to market osteoarthritis drug and complementary products it will acquire or license.